Join
Live feed
·
INSIDERFilingvia Quantisnow
Alnylam Pharmaceuticals Inc. logo

EVP Chief R&D Garg Pushkal converted options into 1,908 shares and sold $1,533,100 worth of shares (4,627 units at $331.34), decreasing direct ownership by 11% to 22,129 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.